CV Sciences (CVSI) Stock Price, News & Analysis

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Key Stats

• Today's Range: $0.03 to $0.05
• 50-Day Range: $0.04 to $0.05
• 52-Week Range: $0.03 to $0.10
• Volume: 794,276 shs
• Average Volume: 235,176 shs
• Market Capitalization: $7.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CV Sciences Stock Analysis - MarketRank™

CV Sciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CV Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CV Sciences is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CV Sciences is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CV Sciences has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of CV Sciences have been sold short.

Short Interest Ratio / Days to Cover

CV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CV Sciences has recently decreased by 54.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CV Sciences does not currently pay a dividend.

Dividend Growth

CV Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of CV Sciences have been sold short.

Short Interest Ratio / Days to Cover

CV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CV Sciences has recently decreased by 54.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.60

News Sentiment

CV Sciences has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CV Sciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CV Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of CV Sciences is held by insiders.

CVSI Stock Analysis - Frequently Asked Questions

How have CVSI shares performed this year?

CV Sciences' stock was trading at $0.0354 on January 1st, 2024. Since then, CVSI shares have increased by 20.6% and is now trading at $0.0427.
View the best growth stocks for 2024 here.

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The firm earned $5.13 million during the quarter, compared to analysts' expectations of $5.12 million. CV Sciences had a negative net margin of 15.95% and a negative trailing twelve-month return on equity of 89.87%.

How do I buy shares of CV Sciences?

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI).

Company Calendar

• Last Earnings: 8/12/2021
• Today: 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CVSI
• Previous Symbol: NASDAQ:CVSI
• CUSIP: N/A
• CIK: 1510964
• Web: www.cvsciences.com
• Phone: (866) 290-2157
• Fax: 619-876-4321
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $3.10 million
• Net Margins: -15.95%
• Pretax Margin: -15.97%
• Return on Equity: -89.87%
• Return on Assets: -27.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.12
• Quick Ratio: 0.25

Sales & Book Value

• Annual Sales: $16 million
• Price / Sales: 0.49
• Cash Flow: $0.02 per share
• Price / Cash Flow: 2.18
• Book Value: $0.02 per share
• Price / Book: 2.14

Miscellaneous

• Outstanding Shares: 184,794,000
• Free Float: 182,392,000
• Market Cap: $7.89 million
• Optionable: Not Optionable
• Beta: 0.59